Hortobagyi to deliver Karnofsky lecture; Brugge–Science of Oncology lecture; Wolmark–Gianni Bonadonna lecture

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

Ivan Borrello, medical director of the Myeloma, Bone Marrow Transplant and Cell Therapies Program at Tampa General Hospital’s Cancer Institute, watched as flood waters from Hurricane Helene heaved against a contraption called the AquaFence, which is, as the name suggests, a water-impermeable barrier made of marine-grade laminate and various metals that can withstand storm surges of up to 15 feet above sea level.

October 18, 2024

Vol.50 No.39

By Claire Marie Porter

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids

Hurricane Milton via satellite on Wednesday. Source: NOAA/NESDISSTAR GOES-EastMilton—the second hurricane in as many weeks—ripped through America’s southeast, causing severe flooding, washing away bridges, knocking out power and water supply.

October 11, 2024

Vol.50 No.38

By Claire Marie Porter

Clinical Roundup

ASCO launches health equity learning collaborative

The American Society of Clinical Oncology has brought together 12 groups of cancer care delivery professionals to initiate a program aimed to improve health equity.

August 02, 2024

Vol.50 No.31

Guest Editorial

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon.

June 21, 2024

Vol.50 No.25

By Don S. Dizon, Chunkit Fung, Paula Chambers Raney, Charles Kamen and Shail Maingi

Clinical

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

Treatment with an indefinite course of osimertinib dramatically improves progression-free survival for patients with stage 3 non-small cell cancer, according to the results of the LAURA trial. The median PFS was 39.1 months in the osimertinib group, compared to 5.6 months with the placebo group.

June 07, 2024

Vol.50 No.23

By Jacquelyn Cobb and McKenzie Prillaman

Clinical Trials & Tribulations

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients. xxx:more

June 07, 2024

Vol.50 No.23

By Rebecca Sutphen

Hortobagyi to deliver Karnofsky lecture; Brugge–Science of Oncology lecture; Wolmark–Gianni Bonadonna lecture

YOU MAY BE INTERESTED IN

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids

ASCO launches health equity learning collaborative

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

Renew today!

Subscriber content

Never miss an issue!

Login

Hortobagyi to deliver Karnofsky lecture; Brugge–Science of Oncology lecture; Wolmark–Gianni Bonadonna lecture

YOU MAY BE INTERESTED IN

Climate change exacerbates cancer disparitiesAmid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on scheduleHelene knocks out Baxter facility, creating shortage of IV fluids

ASCO launches health equity learning collaborative

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

Never miss an issue!

Login

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids